Valsartan. A review of its pharmacology and therapeutic use in essential hypertension

Drugs

Volumn 54, Issue 2, 1997, Pages 299-311

  Markham, Anthony ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; PEPTIDE HORMONE ANTAGONIST; VALSARTAN;

CLINICAL TRIAL; COUGHING; DISEASE SEVERITY; ESSENTIAL HYPERTENSION; FATIGUE; HEADACHE; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; META ANALYSIS; REVIEW; VERTIGO;

EID: 0030750293     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199754020-00009     Document Type: Review

References (50)

1. Cody RJ. The clinical potential of renin inhibitors and angiotensin antagonists. Drugs 1994 Apr; 47: 586-98
2. Awan NA, Mason DT. Direct selective blockade of the vascular angiotensin II receptors in therapy for hypertension and severe congestive heart failure. Am Heart J 1996 Jan; 131: 177-85
3. Tallant EA, Ferrario CM. Biology of angiotensin II receptor inhibition with a focus on losartan; a new drug for the treatment of hypertension. Expert Opin Invest Drug 1996 Sep: 5: 1201-14
4. Bauer JH, Reams GP. The angiotensin II type I receptor antagonists: a new class of antihypertensive drugs. Arch Intern Med 1995 Jul 10; 155: 1361-8
5. Timmermans PBMWM. Wong PC, Chiu AT, et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993; 45 (2): 205-51
6. 1-reeeptor subtype. Br J Pharmacol 1993 Oct; 110: 761 -71
7. Criseione L. Bradley WA. Bühlmayer P, et al. Valsartan: preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc Drug Rev 1995; 13 (3): 230-50
8. 1 reeeptors. Regul Pept 1995 Nov 10; 59: 303-11
9. Tschudi MR, Luscher TF, Characterization of contractile endothelin and angiotensin receptors in human resistance arteries: evidence for two endothelin and one angiotensin receptor. Biochem Biophys Res Commun 1994 Oct 28: 204: 685-90
10. Müller P, Flesch G, de Gasparo M. et al. Single- and multipledose phase I trials with the angiotensin II antagonist valsartan [abstract]. J Hypertens 1993 Dec: 11 Suppl. 5: S459-60
11. Müller P. Cohen T, de Gasparo M. et al. Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects. Eur J Clin Pharmacol 1994; 47 (3): 231-45
12. Harb G, Morgan JM. Prasad P, et al. The pressor inhibitory effect of angiotensin-II antagonist (valsartan, CGP 48933) on angiotensin-II infusions in healthy subjects [abstraet]. J Invest Med 1995 Apr; 43 Suppl. 2: 239A
13. Faulhaber HD, Stein G. Jansa U, et al. Valsartan, a new angiotensin II receptor blocker: Tolerabilily and effect on renal function in treated hypertensive patients with stable renal insufficiency (protocol 26). Novartis. 1997. (Data on file)
14. Arzilli F, Favilla S, Motolese M, et al. Valsartan, a new angiotensin II receptor antagonist. Tolerability and effects on renal function in patients with renovascular arterial hypertension (protocol 25). Novartis. 1997. (Data on file)
15. Warman LP, Griffin MA, Ledingham JM, et al. The effects of valsartan on mesenteric resistance vessel structure, heart weight and blood pressure in the NZ GH rat [abstract]. 28th Annu Sci Meet ASCEPT 1994 Dec: 1: 123
16. Pham LTV, Ledingham JM, Cross MA, et al. A comparison of the effects of valsartan and enalapril on blood pressure and LV mass in New Zealand GH-rats [abstract]. 28th Annu Sci Meet ASCEPT 1994 Dec; 1: 97
17. Flesch G, Mueller P, Lloyd P. Absolute bioavailability and pharmacokinetics of valsartan, an angiotensin II receptor antagonist, in man. Novartis, 1996. (Data on file)
18. Müller P, Flesch G, de Gasparo M, et al. Pharmacokinetics and pharmacodynamic effects of the angiotensin II antagonist valsartan at steady state in healthy, normotensive sujects. Eur J Pharmacol. In press
19. Colussi DM, Parisot C, Rossolino ML, et al. Protein binding in plasma of valsartan, a new angiotensin II receptor antagonist. J Clin Pharmacol 1997; 37-. 214-21
20. Kalbag J, Prasad P, Redalieu E, et al. Plasma concentrations and antihypertensive effect of 10 to 160 mg doses of valsartan (VAL) in hypertensive patients [abstract]. Pharm Res 1994 Oct: 11 Suppl.: S367
21. 14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica 1997; 27(1): 59-71
22. Brookman LJ, Rolan PE, Benjamin IS, et al. Pharmacokinetics of valsartan in patients with liver disease. Novartis, 1996. (Data on file)
23. Prasad P, Mangat S, Choi L, et al. Effect of renal function on the pharmacokinetics of valsartan. Clin Drug Invest 1997: 13 (4): 207-14
24. Sioufi A, Marfil F, Jaouen A, et al. The effect of age on the Pharmacokinetics of valsartan [abstract]. Eur J Drug Metab Pharmacokinet 1996 (Special issue): 86
25. Strödter D, Zeissig I, Heath R, et al. Angiotensin-II antagonist CGP-48933 (valsartan): results of a double-blind, placebocontrolled multicenter study [in German]. Nieren Hoch 1994 May; 23: 217-20
26. Joint National Committee on Detection Evaluation and Treatment of High Blood Pressure. The Fifth Report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC V). Arch Intern Med 1993 Jan 25; 153: 154-83
27. World Health Organization Guidelines Subcommittee. 1993 Guidelines for the managment of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertens 1993; 11: 905-18
28. Oparil S, Dyke S, Harris F, et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996; 18 (5): 797-810
29. Chrysant SG, Holtzman J, Lewin A, et al. Results of a pilot dose-ranging trial of valsartan in patients with essential hypertension [abstract]. Am J Hypertens 1996 Apr; 9: 121A (Pt 2)
30. Chen S, James D. Hester A, et al. Long term safety, tolerability and efficacy of valsartan: results from one and two year trials (protocol 31E/11E). Novartis, 1996. (Data on file)
31. Neutel J, Weber M, Pool J, et al. Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours (protocol 31 ABPM). Novartis. 1996. (Data on file)
32. Valsartan: long term efficacy and tolerability compared to lisinopril in elderly patients with essential hypertension (protocol 28). Novartis. 1996. (Data on file)
33. Black HR. Graff A, Shute D, et al. Valsartan. a new angiotensin II antagonist for the treatment of essential hypertension. Efficacy, tolerabilty and safely compared to an angiotensin converting enzyme inhibitor lisinopril (protocol 50). Novartis, 1997. (Data on file)
34. Grün A, Francillon A, Bodin F, et al. A comparison of the efficacy and tolerability of a new angiotensin II antagonist, valsartan. with enalapril in patients with mild-to-moderate essential hypertension [abstract]. Eur Heart J 1995 Aug; 16 Suppl.: 61
35. Holwerda NJ, Fogari R, Angeli P, et al. Valsartan. a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens 1996; 14: 1147-51
36. Mallion J-M, Boutelant S, Chabaux P, et al. Valsartan. a new angiotensin II antagonist: efficacy and tolerability compared with an angiotensin converting enzyme inhibitor enalapril in essential hypertension. Blood Pres Mon. In press
37. Oddou-Stock P, Gatlin M, Kohi P, et al. Comparison of the efficacy of two angiotensin II antagonists, valsartan and losartan. in essential hypertension [abstract]. Am J Hypertens 1997; 10 (4): 84A
38. Hegner G, Faust G, Freytag F, et al. Valsartan. a new angiotensin II antagonist for the treatment of essential hypetension: efficacy and safety compared to hydrochlorothiazide. Eur J Pharmacol 1997; 52: 173-177
39. Corea L, Cardoni O, Fogari R, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther 1996 Sep; 60: 341-6
40. Cifkova R, Botteri F, Mann J, et al. Comparison of the angiotensin II antagonist valsartan with the β-blocker atenolol in patients with severe essential hypertension [abstract]. Am J Hypertens 1997; 10 (4): 114A
41. Perico N, Spormann D, Peruzzi E, et al. Efficacy and tolerability of valsartan compared with lisinopril in patients with hypertension and renal insufficiency. Clin Drug Invest. In press
42. Valsartan facts and figures. Novartis, 1996. (Data on file)
43. Benz J, Oshrain C, Henry D. et al. Valsartan. a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol 1997; 37: 101-7
44. Ciba-Geigy Corporation. Valsartan prescribing information. Summit (NJ) USA
45. Stokes J, Kannel WB, Wolf PA, et al. Blood pressure as a risk factor for cardiovascular disease. The Framingham study - 30 years of follow-up. Hypertension 1989 May; 13 Suppl. 5: 133-5
46. Swales JD. Management guidelines for hypertension: is anyone taking notice? J Hum Hypertens 1995; 9: S9-S13
47. Kaplan NM. Gifford Jr RW. Choice of initial therapy for hypertension. JAMA 1996 May 22-29; 275: 1577-80
48. Goa KL, Wagstaff AJ, Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996 May; 51: 820-45
49. Foote EF, Halstenson CE. New therapeutic agents in the management of hypertension: angiotensin II-receptor antagonists and renin inhibitors. Ann Pharmacother 1993 Dec: 27: 1495-503
50. Dahlöf B. Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review. J Hum Hypertens 1995 Nov; 9 Suppl. 5: 37-44